LLY · Market open
$1,189.51
+3.05% today·exchange $1,188.78
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
Pharmaceutical Technology · 1h ago
Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight
PR Newswire · 2h ago
Lilly’s latest China drug deal; Immunovant’s setback in lupus
BioPharma Dive · 2h ago
Eli Lilly's Onswik Insulin Injection Gets FDA Approval for Adults with Type 2 Diabetes
MT Newswires · 5h ago
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
Business Wire · 5h ago
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
PR Newswire · 6h ago
Headlines from Yahoo Finance. Not investment advice.
